Braftovi 75 mg hard capsules
Sponsors
Asociacion Grupo Tratamiento De Tumores Digestivos, Unicancer, Unicancer, European Organisation For Research And Treatment Of Cancer, Unicancer, Gruppo Oncologico Del Nord Ovest
Conditions
Advanced Biliary Cancer (ABC)BRAF V600 mutation–positive unresectable or metastatic melanomaBRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectableBRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCERBRAF(V600) mutation-positive melanoma with brain metastasis (MBM)BRAFV600E-mutant metastatic Non-small Cell Lung CancerMelanomaMetastatic colorectal cancer
Phase 2
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF V600E mutated MSS initially resectable or potentially resectable advanced colorectal cancer.
RecruitingCTIS2022-502413-29-00
Start: 2024-01-22Target: 70Updated: 2024-10-30
BEPCOME-MB: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone in patients with BRAFV600 mutationpositive melanoma with brain metastasis
Active, not recruitingCTIS2023-505302-42-00
Start: 2022-09-05Target: 150Updated: 2025-04-07
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
RecruitingCTIS2023-509204-15-00
Start: 2024-05-17Target: 94Updated: 2025-10-31
Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study
Active, not recruitingCTIS2023-509088-26-00
Start: 2024-07-22Target: 16Updated: 2024-06-21
EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN)
Active, not recruitingCTIS2023-505376-30-00
Start: 2018-10-30Target: 264Updated: 2026-01-22
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING IN PATIENTS WITH BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
Not yet recruitingCTIS2024-514107-34-00
Target: 30Updated: 2025-11-03
C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer
CompletedCTIS2024-515929-28-00
Start: 2019-08-02End: 2025-08-14Target: 59Updated: 2025-08-19
IFCT-1904 ENCO-BRAF A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Active, not recruitingCTIS2024-515944-22-00
Start: 2021-01-19Target: 119Updated: 2024-10-31
Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlimab in patients with BRAF mutated melanoma and symptomatic brain metastases.
RecruitingCTIS2024-513375-40-00
Start: 2025-05-16Target: 33Updated: 2025-11-25